Bristol Myers Squibb (BMY) Stock Forecast: What Could Drive It in 2026
Short answer
No one can reliably forecast BMY's price, and Walnut does not publish targets. What is useful is the setup. For Bristol Myers Squibb, the drivers that could push it higher are real, and so are the risks that could weigh on it. Below is each side plus a framework to form your own view. This is descriptive, not a prediction or a recommendation.
What could drive Bristol Myers Squibb (BMY) higher?
1. New product portfolio ramp.
Bristol Myers is shifting revenue weight toward a newer set of growth drivers including Reblozyl, Opdualag, Camzyos, Breyanzi, Sotyktu, and Cobenfy. Management frames these as the engine meant to offset legacy patent losses. The success of this transition, especially Cobenfy in neuropsychiatry, is central to the multi-year growth story and to whether the company can return to durable top-line expansion.
2. Oncology and immunology depth.
The company has a deep oncology franchise anchored by Opdivo plus cell therapies (Breyanzi, Abecma) and a broad immunology effort led by the oral psoriasis drug Sotyktu. Expanding indications, subcutaneous formulations (Opdivo Qvantig), and combination regimens can extend the life and reach of these franchises, supporting revenue even as older products fade.
3. Pipeline and disciplined dealmaking.
Bristol Myers has a history of large, focused acquisitions (Celgene, MyoKardia, Karuna, Mirati, RayzeBio) to add pipeline assets and new modalities such as radiopharmaceuticals. A productive late-stage pipeline plus targeted business development is how the company aims to replenish revenue and address the looming exclusivity losses on its biggest legacy products.
4. Strong cash generation.
The branded pharma model produces substantial free cash flow, which funds a meaningful dividend, share repurchases, debt reduction after acquisitions, and continued research spending. This cash engine gives management flexibility to manage the patent cliff while still investing in the next generation of medicines.
What could weigh on BMY?
The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook. High debt from dealmaking and litigation exposure add further uncertainty.
How to think about a BMY forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the BMY guide and whether BMY is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the BMY outlook
The honest bottom line: Bristol Myers Squibb (BMY)'s outlook hinges on whether its drivers (above) outpace its risks, and no one can promise which wins. Treat any BMY forecast as a scenario, not a certainty, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around BMY with Walnut
Use Bristol Myers Squibb as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Bristol Myers Squibb (BMY)?
+
No one can reliably predict where BMY will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Bristol Myers Squibb higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive BMY higher?
+
The main growth drivers are New product portfolio ramp; Oncology and immunology depth; Pipeline and disciplined dealmaking. Whether they play out is the real question, not a guaranteed path.
What are the risks to BMY?
+
The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook. High debt from dealmaking and litigation exposure add further uncertainty.
Will BMY stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Bristol Myers Squibb's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is BMY a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the BMY "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.